Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes
The optimal MM treatment sequences begin with daratumumab-containing regimens in FL and improve outcomes compared with alternative sequences.
Authors
- Sara Bringhen
- Patrizio Armeni (ORCID: https://orcid.org/0000-0003-3150-3332)
- Cristina Entrala Cerezo
- J. Mendes (ORCID: https://orcid.org/0000-0001-7535-8750)
- Maria Teresa Petrucci (ORCID: https://orcid.org/0000-0003-0688-4882)
Institutions
- Policlinico Umberto I (IT)
- Janssen (United States) (US)
- Piedmont Reference Center for Epidemiology and Cancer Prevention (IT)
- Bocconi University (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Hematology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1080/16078454.2024.2432815
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Janssen Research and Development